Clinical-stage biotherapeutics company PureTech Health plc (Nasdaq: PRTC) (LSE: PRTC) announced on Wednesday that it presented research at the CHEST 2024 Annual Meeting, underscoring the burden of idiopathic pulmonary fibrosis (IPF) and the innovative use of Bayesian statistical analysis in its Phase 2b ELEVATE IPF trial of LYT-100 (deupirfenidone).

These presentations highlighted the significant impact of IPF on patients, including symptoms like shortness of breath, fatigue and cough, and revealed gaps in disease management, particularly between interstitial lung disease (ILD) centers and community pulmonary practices.

The clinical abstract discussed the application of a Bayesian approach in the ELEVATE IPF trial, designed to improve statistical power and minimise the number of patients on placebo. The trial evaluates the safety, tolerability and efficacy of LYT-100, a deuterated form of pirfenidone, and compares two doses of the drug against placebo over 26 weeks. Topline results are anticipated by the end of 2024, with plans for a Phase 3 trial following positive outcomes.

LYT-100 aims to offer improved tolerability compared to existing IPF treatments, potentially allowing patients to maintain higher therapeutic doses for longer durations. Pending successful trials, LYT-100 could serve as a next-generation therapy for IPF, addressing both unmet needs and a broader patient population.